Abbott's Esprit BTK Dissolvable Stent Approved By Health Canada

rttnews
2025.09.29 12:37
portai
I'm PortAI, I can summarize articles.

Abbott Laboratories has received approval from Health Canada for its Esprit BTK Everolimus Eluting Resorbable Scaffold System, a dissolvable stent designed to treat chronic limb threatening ischemia (CLTI) below-the-knee. This device helps keep arteries open and delivers the drug everolimus to aid healing before it fully dissolves, addressing the needs of over 800,000 Canadians suffering from Peripheral Artery Disease (PAD).

Abbott Laboratories (ABT) on Monday announced that Health Canada has approved its dissolvable stent, the Esprit BTK Everolimus Eluting Resorbable Scaffold System.

The device is used to treat people with chronic limb threatening ischemia (CLTI) below-the-knee (BTK). It keeps arteries open and delivers the drug everolimus to support healing before the stent fully dissolves.

More than 800,000 Canadians are living with Peripheral Artery Disease (PAD). CLTI is a severe form of PAD in which arteries become clogged with plaque, blocking blood flow and oxygen to the lower leg and foot. People with CLTI often experience severe pain and non-healing open wounds.

For comments and feedback contact: editorial@rttnews.com

Business News

Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.